These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35154988)

  • 21. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spectrum of Findings Seen in Patients With
    Kierans AS; Lutfi A; Afghan MK; Khan S; Javaid S; Currie BM; Rocca J; Samstein B; Golden E; Popa E; Hissong E; Kasi PM
    Int J Surg Pathol; 2024 Sep; ():10668969241271397. PubMed ID: 39314068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
    Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ivosidenib: First Global Approval.
    Dhillon S
    Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
    Ricci AD; Rizzo A
    Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting.
    Salati M; Caputo F; Baldessari C; Galassi B; Grossi F; Dominici M; Ghidini M
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ivosidenib for advanced IDH1-mutant cholangiocarcinoma.
    Gervaso L; Pellicori S; Fazio N
    Lancet Oncol; 2020 Aug; 21(8):e370. PubMed ID: 32758465
    [No Abstract]   [Full Text] [Related]  

  • 28. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
    Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
    Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma.
    Yang Y; Yuan J; Liu Z; Cao W; Liu P
    Front Oncol; 2022; 12():972550. PubMed ID: 35965590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply.
    Abou-Alfa GK; Pandya SS; Zhu AX
    Lancet Oncol; 2020 Aug; 21(8):e371. PubMed ID: 32758466
    [No Abstract]   [Full Text] [Related]  

  • 31. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of bile microbiota in cholelithiasis, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and pancreatic cancer.
    Li Z; Chu J; Su F; Ding X; Zhang Y; Dou L; Liu Y; Ke Y; Liu X; Liu Y; Wang G; Wang L; He S
    Am J Transl Res; 2022; 14(5):2962-2971. PubMed ID: 35702117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.
    Gringeri E; Gambato M; Sapisochin G; Ivanics T; Lynch EN; Mescoli C; Burra P; Cillo U; Russo FP
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32380750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.
    Stemer G; Rowe JM; Ofran Y
    Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy.
    Nassereddine S; Lap CJ; Tabbara IA
    Onco Targets Ther; 2019; 12():303-308. PubMed ID: 30643428
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.